For routine prophylaxis in adults and children ages 6 years and older with hemophilia A or B, with or without inhibitors

Only HYMPAVZI is a once-weekly, fixed-dose^† pen that delivers proven bleed protection* and demonstrated safety^‡

A set dose comes in each pen, so you don't need to mix or measure

Once-weekly dosing designed to fit into your schedule

Injected under the skin, not into a vein

Why HYMPAVZI

*_{In the phase 3 BASIS study, the primary objective was to measure the annualized bleed rate (ABR) of treated bleeds vs on-demand factor-based treatment without inhibitors, vs factor-based prophylaxis without inhibitors, and vs on-demand bypass treatment with inhibitors after 12 months on HYMPAVZI. 92% reduction in treated bleeds on HYMPAVZI compared with on-demand factor-based treatment without inhibitors (3.2 ABR vs 39.9 ABR). 35% reduction in treated bleeds on HYMPAVZI compared with routine prophylaxis treatment without inhibitors (5.1 ABR vs 7.9 ABR). 93% reduction in treated bleeds on HYMPAVZI compared with on-demand bypass treatment with inhibitors (1.4 ABR vs 19.8 ABR). In the phase 3 BASIS KIDS study, the primary objective was to measure the ABR of treated bleeds in patients with and without inhibitors for 12 months on HYMPAVZI. Patients ages 6 to less than 18 without inhibitors taking HYMPAVZI had an ABR of 1.8 (compared with an estimated ABR of 3.6, based on past bleeding history). Patients ages 6 to less than 18 with inhibitors previously on on-demand treatment taking HYMPAVZI had an ABR of 1.4 (compared with an estimated ABR of 18.9, based on past bleeding history with an on-demand bypassing agent). Individual results may vary.}

†_{HYMPAVZI is available in 75 mg and 150 mg pens. For children ages 6 to less than 12, the first dose (loading dose) is 150 mg on day 1. Then a weekly (maintenance) dose of 75 mg as prescribed by your healthcare provider. For adults and adolescents 12+, the first dose (loading dose) is 300 mg on day 1. Then a weekly (maintenance) dose of 150 mg as prescribed by your healthcare provider. If more than 1 injection is required to deliver a complete dose, administer each injection at a different site.}

‡_{In the BASIS and BASIS KIDS studies, the most common adverse reactions included injection site reactions, headache, pyrexia, arthralgia, diarrhea, pruritus, and rash.}

Bleed protection with HYMPAVZI

Treated bleeds

Joint bleeds

Target joint bleeds

Spontaneous bleeds

Total bleeds

HYMPAVZI has been studied in 2 clinical trials. See study results.

The BASIS study

Adults and adolescents 12+ with or without inhibitors

Explore now

The BASIS KIDS study

Children 6 to less than 18 with or without inhibitors

Explore now